Vaccinex, Inc. Faces Delisting Concerns
Ticker: VCNX · Form: 8-K · Filed: Dec 17, 2024 · CIK: 1205922
| Field | Detail |
|---|---|
| Company | Vaccinex, Inc. (VCNX) |
| Form Type | 8-K |
| Filed Date | Dec 17, 2024 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001, $2.5 million |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-rules, 8-k
TL;DR
Vaccinex might get kicked off the exchange, check the details.
AI Summary
Vaccinex, Inc. filed an 8-K on December 17, 2024, reporting a notice of delisting or failure to satisfy continued listing rules, along with other events and financial statements. The company is incorporated in Delaware and its principal executive offices are located in Rochester, New York.
Why It Matters
This filing indicates potential issues with Vaccinex, Inc.'s continued listing on an exchange, which could significantly impact its stock value and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's operations and stock value.
Key Numbers
- 001-38624 — SEC File Number (Identifies the company's filing with the SEC.)
- 16-1603202 — IRS Employer Identification No. (Tax identification number for the company.)
Key Players & Entities
- Vaccinex, Inc. (company) — Registrant
- Delaware (jurisdiction) — State of incorporation
- Rochester, New York (location) — Principal executive offices
- 1895 Mount Hope Avenue (address) — Business address
FAQ
What specific listing rule or standard has Vaccinex, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that Vaccinex, Inc. has failed to satisfy, only that a notice has been issued.
What is the date of the earliest event reported in this 8-K filing?
The earliest event reported is dated December 16, 2024.
What is Vaccinex, Inc.'s primary business activity based on its SIC code?
Vaccinex, Inc.'s Standard Industrial Classification (SIC) code is 2834, which corresponds to Pharmaceutical Preparations.
Where are Vaccinex, Inc.'s principal executive offices located?
Vaccinex, Inc.'s principal executive offices are located at 1895 Mount Hope Avenue, Rochester, New York 14620.
What is the filing date of this 8-K report?
This 8-K report was filed on December 17, 2024.
Filing Stats: 785 words · 3 min read · ~3 pages · Grade level 12.4 · Accepted 2024-12-17 09:32:59
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share VCNX Nasdaq Capital Marke
- $2.5 million — ule 5550(b)(1) to maintain a minimum of $2.5 million in stockholders' equity for continued l
Filing Documents
- d875332d8k.htm (8-K) — 25KB
- d875332dex991.htm (EX-99.1) — 8KB
- g875332g0731020058828.jpg (GRAPHIC) — 3KB
- 0001193125-24-280155.txt ( ) — 158KB
- vcnx-20241216.xsd (EX-101.SCH) — 3KB
- vcnx-20241216_lab.xml (EX-101.LAB) — 17KB
- vcnx-20241216_pre.xml (EX-101.PRE) — 11KB
- d875332d8k_htm.xml (XML) — 3KB
Forward-Looking Statements
Forward-Looking Statements Except for the factual statements made herein, information contained in this report consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks, uncertainties and assumptions that are difficult to predict. Words such as "will," "may," "intends," "plans," and similar expressions, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. For example, there can be no assurance that the Company's Common Stock will be quoted on the OTC Markets Group. The risks included are not exhaustive; for a more detailed description of these uncertainties and other factors, see the other risk factors set forth from time to time in the Company's filings with the Securities and Exchange Commission, copies of which are available for free at www.sec.gov or upon request from the Company's Investor Relations Department. All information provided in this Form 8-K is as of the date hereof and the Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law. Item9.01 Financial Statements and Exhibits. The following exhibits are filed herewith: Exhibit Number Exhibit Description 99.1 Press Release, dated December 17, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vaccinex, Inc. Date: December 17, 2024 By: /s/ Jill Sanchez Jill Sanchez Chief Financial Officer